TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
-0.55%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.51B
AUM Growth
+$1.51B
(+8%)
Cap. Flow
+$174M
Cap. Flow
% of AUM
11.53%
Top 10 Holdings %
Top 10 Hldgs %
37.54%
Holding
194
New
40
Increased
62
Reduced
19
Closed
11
Top Buys
| 1 |
Galapagos
GLPG
|
$40.2M |
| 2 |
Relay Therapeutics
RLAY
|
$18.5M |
| 3 |
Replimune Group
REPL
|
$18.2M |
| 4 |
Legend Biotech
LEGN
|
$14.6M |
| 5 |
Immunocore
IMCR
|
$13.3M |
Top Sells
| 1 |
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
|
$22.8M |
| 2 |
Kezar Life Sciences
KZR
|
$19.6M |
| 3 |
iTeos Therapeutics
ITOS
|
$16.8M |
| 4 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$13M |
| 5 |
Immunome
IMNM
|
$10.5M |
Sector Composition
| 1 | Healthcare | 94.65% |
| 2 | Technology | 1.65% |
| 3 | Communication Services | 1.35% |
| 4 | Consumer Discretionary | 0.56% |
| 5 | Financials | 0.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Tarsus Pharmaceuticals
TARS
$2.47B
| $125M | 8.26% | 2,254,797 | – | – |
|
2
Aurinia Pharmaceuticals
AUPH
$1.58B
| $75.7M | 5.01% | 8,429,500 +1,200,000 | +17% | +$10.8M |
|
|
3
Galapagos
GLPG
$2.07B
| $59.4M | 3.93% | 2,161,200 +1,461,200 | +209% | +$40.2M |
|
4
Evolus
EOLS
$494M
| $55.2M | 3.65% | 4,997,399 +150,000 | +3% | +$1.66M |
|
5
Mirum Pharmaceuticals
MIRM
$3.71B
| $51.2M | 3.38% | 1,237,107 -50,000 | -4% | -$2.07M |
|
6
Viridian Therapeutics
VRDN
$1.5B
| $47.8M | 3.16% | 2,492,925 +250,000 | +11% | +$4.79M |
|
|
7
Immunocore
IMCR
$1.62B
| $45.9M | 3.04% | 1,555,600 +450,000 | +41% | +$13.3M |
|
8
KalVista Pharmaceuticals
KALV
$678M
| $41.5M | 2.74% | 4,893,847 +572,300 | +13% | +$4.85M |
|
|
9
Relay Therapeutics
RLAY
$619M
| $33.2M | 2.2% | 8,068,058 +4,500,000 | +126% | +$18.5M |
|
|
10
Replimune Group
REPL
$422M
| $32.7M | 2.16% | 2,700,000 +1,500,000 | +125% | +$18.2M |
|
11
PTC Therapeutics
PTCT
$3.92B
| $31.6M | 2.09% | 700,000 | – | – |
|
12
BioNTech
BNTX
$24B
| $30.8M | 2.04% | 270,000 | – | – |
|
13
Acadia Pharmaceuticals
ACAD
$4.38B
| $27.5M | 1.82% | 1,500,000 | – | – |
|
|
ITCI
14
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $25.1M | 1.66% | 300,000 | – | – |
|
15
Vaxcyte
PCVX
$4B
| $24.6M | 1.62% | 300,000 | – | – |
|
16
Dynavax Technologies
DVAX
$1.19B
| $23.6M | 1.56% | 1,850,000 -50,000 | -3% | -$639K |
|
|
LENZ
17
LENZ Therapeutics
LENZ
$1.1B
| $22.1M | 1.47% | 766,940 | – | – |
|
18
Neurocrine Biosciences
NBIX
$13.8B
| $20.5M | 1.35% | 150,000 | – | – |
|
19
Altimmune
ALT
$338M
| $19.8M | 1.31% | 2,750,000 | – | – |
|
20
NVIDIA
NVDA
$4.24T
| $19.1M | 1.27% | 142,569 -5,163 | -3% | -$693K |
|
21
AnaptysBio
ANAB
$569M
| $17.6M | 1.17% | 1,330,879 | – | – |
|
22
ANI Pharmaceuticals
ANIP
$2.03B
| $17.6M | 1.16% | 317,500 -132,500 | -29% | -$7.32M |
|
23
Jazz Pharmaceuticals
JAZZ
$7.75B
| $17.2M | 1.14% | 140,000 | – | – |
|
24
Zymeworks
ZYME
$1.12B
| $16.1M | 1.07% | 1,100,000 | – | – |
|
25
Atea Pharmaceuticals
AVIR
$267M
| $16M | 1.06% | 4,788,912 +181,852 | +4% | +$609K |
|